AliveCor’s personal electrocardiogram (ECG) KardiaMobile 6L has been authorised by the US Food and Drug Administration to monitor cardiac adverse events associated with two drugs being used off-label to treat Covid-19, hydroxychloroquine and azithromycin.

KardiaMobile6L allows doctors to measure a patient’s QTc, or heart rate corrected interval. Abnormal prolongation of QTc leaves patients at risk of arrhythmia, sudden cardiac arrest and sometimes cardiac death. So better knowing a patient’s QTc allows doctors to make assessments and decisions about the medication they are being prescribed to treat Covid-19.

AliveCor CEO Priya Abani said: “At AliveCor, we are committed to providing life-saving cardiological services to those who need them most. The benefits of remote, personal ECG measurement have never been clearer.

“We are thankful to the FDA for issuing timely guidance to help expand the availability of our device to assist in the treatment of COVID-19 during this global health emergency.”

AliveCor’s QTc measurement technology has been developed in collaboration with the Mayo Clinic since 2017. The clinic’s Windland Smith Rice Genetic Heart Rhythm Clinic and Sudden Death Genomics Laboratory director Michael J. Ackerman added: “AliveCor’s KardiaMobile 6L technology can play a key role in obtaining the patient’s QTc as a vital sign to help guide the rapid and safe use of these drugs.

“In addition, the patient’s QTc can be obtained without exposing ECG technicians to affected patients which helps to conserve personal protection equipment (PPE) and thereby expand the capacity of our strained medical resources.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.